Genetic association of gemcitabine/carboplatin-induced leukopenia and neutropenia in non-small cell lung cancer patients using whole-exome sequencing

Lung cancer is the second most common cancer in the United States with a 5-year relative survival rate of only 18 % [1]. A widely used non-small cell lung cancer (NSCLC) chemotherapy treatment is gemcitabine in combination with carboplatin which is also used in the treatment of other solid tumors such as bladder, ovarian and breast cancer. Gemcitabine/carboplatin treatment is known to cause severe toxicity that can lead to the need for postponed treatment, reduced doses and in some cases even discontinuation of treatment [2].

Source: Lung Cancer - July 11, 2020 Category: Cancer & Oncology Authors: Anna Svedberg, Niclas Bj örn, Benjamín Sigurgeirsson, Sailendra Pradhananga, Eva Brandén, Hirsh Koyi, Rolf Lewensohn, Luigi De Petris, María Apellániz-Ruiz, Cristina Rodríguez-Antona, Joakim Lundeberg, Henrik Gréen Source Type: research